Markets
Outlook Therapeutics, Inc. (OTLK)
OTLKNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.4809
-0.0001 (-0.02%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $0.4810 –
-0.02% 1D
- Market cap
- $117.10m
- P/E
- –
- EPS, last 4 quarters
- $-0.6900
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.1611 to $2.54
- Average volume
- –
- Previous close
- $0.4810
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $7.25, +1407.6% from here
$4.00now $0.4809$10.50
Earnings
next estimate $-0.0800Next report Dec 18, 2026
Sep 2025
+4.3%
Dec 2025
-29.4%
Mar 2026
-33.3%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | $1.50m | $127.0k | $9,000 |
| Gross profit | – | $1.07m | -$22.0k | -$8,000 |
| Operating income | -$12.39m | -$15.75m | -$14.03m | -$10.81m |
| Net income | -$46.36m | -$20.15m | -$4.45m | -$20.32m |
News
8 latest- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer RTTNews · Oct 9, 2026
- Outlook Therapeutics Highlights LYTENAVA FDA Approval And U.S. Commercial Opportunity RTTNews · Sep 10, 2026
- Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories RTTNews · Aug 29, 2026
- Outlook Therapeutics Appoints Kevin Lundquist As CFO Ahead Of U.S. LYTENAVA Launch; Stock Up RTTNews · Aug 28, 2026
- Monday 8/17 Insider Buying Report: OTLK, MTDR BNK Invest · Aug 17, 2026
- OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales RampZacks · Aug 17, 2026
- Oncobiologics Q3 Earnings Call HighlightsMarketBeat · Aug 14, 2026
- Outlook Therapeutics Reports Q3 Net Loss; Advances U.S. Launch Of LYTENAVA RTTNews · Aug 14, 2026
The company
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- outlooktherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.